Comment from Novo Nordisk Inc.

Summary: Novo Nordisk Inc. opposes the Outsourcing Facilities Association's (OFA) nomination of semaglutide and other bulk drug substances to the 503B Bulks List. The company argues that mass compounding these substances poses significant safety risks to patients, lacks a legitimate clinical need, and undermines the FDA's drug approval process.